Negative immunomagnetic purging of peripheral blood stem cell harvests from breast carcinoma patients reduces tumor cell contamination while not affecting hematopoietic recovery

Paolo Pedrazzoli, Annalisa Lanza, Manuela Battaglia, Gian Antonio Da Prada, Alberto Zambelli, Cesare Perotti, Luisa Ponchio, Laura Salvaneschi, Gioacchino Robustelli Della Cuna

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BACKGROUND. Because tumor contamination of hematopoietic stem cell grafts may influence the outcome in breast carcinoma (BC) patients undergoing high dose chemotherapy (HDC), several ex vivo procedures for the purging of autologous harvests have been investigated. The authors studied the presence of epithelial tumor cells and the growth of hematopoietic progenitors in peripheral blood stem cell (PBSC) collections from patients with metastatic breast carcinoma before and after a purging procedure performed by a negative immunomagnetic BC cell separation. METHODS. Eighteen patients entered the study. Tumor contamination was assessed by conventional immunocytochemistry (ICC) and by a liquid culture assay developed in the study laboratory. Committed and more primitive hematopoietic progenitors were quantitated before and after the negative selection. Ten patients received HDC with purged PBSC support. RESULTS. Before purging, 4 of 18 PBSC collections were found to be contaminated by liquid culture; among these samples, only 1 was positive by ICC. Three of the four positive collections, including the ICC positive sample, became negative after immunomagnetic selection whereas BC cells still were present after the procedure in one harvest. A high recovery of both primitive and mature hematopoietic progenitors was found after the purging procedure. Patients receiving purged PBSC after myeloablation had a prompt and complete hematopoietic reconstitution, and no graft failure was observed at a median follow-up of 1 year. CONCLUSIONS. The preliminary results of the current study suggest that negative selection of BC cells is able to purge PBSC effectively while having no apparent affect on hematopoietic progenitor recovery in vitro and in vivo. (C) 2000 American Cancer Society.

Original languageEnglish
Pages (from-to)2758-2765
Number of pages8
JournalCancer
Volume88
Issue number12
DOIs
Publication statusPublished - Jun 15 2000

Fingerprint

Immunomagnetic Separation
Breast Neoplasms
Immunohistochemistry
Neoplasms
Transplants
Drug Therapy
Cell Separation
Hematopoietic Stem Cells
Epithelial Cells
Peripheral Blood Stem Cells
Growth

Keywords

  • Breast carcinoma
  • Immunomagnetic purging
  • Liquid culture immunocytochemistry
  • Peripheral blood stem cell (PBSC)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Negative immunomagnetic purging of peripheral blood stem cell harvests from breast carcinoma patients reduces tumor cell contamination while not affecting hematopoietic recovery. / Pedrazzoli, Paolo; Lanza, Annalisa; Battaglia, Manuela; Da Prada, Gian Antonio; Zambelli, Alberto; Perotti, Cesare; Ponchio, Luisa; Salvaneschi, Laura; Della Cuna, Gioacchino Robustelli.

In: Cancer, Vol. 88, No. 12, 15.06.2000, p. 2758-2765.

Research output: Contribution to journalArticle

@article{4a211cce2ca9415e81f753c629dba770,
title = "Negative immunomagnetic purging of peripheral blood stem cell harvests from breast carcinoma patients reduces tumor cell contamination while not affecting hematopoietic recovery",
abstract = "BACKGROUND. Because tumor contamination of hematopoietic stem cell grafts may influence the outcome in breast carcinoma (BC) patients undergoing high dose chemotherapy (HDC), several ex vivo procedures for the purging of autologous harvests have been investigated. The authors studied the presence of epithelial tumor cells and the growth of hematopoietic progenitors in peripheral blood stem cell (PBSC) collections from patients with metastatic breast carcinoma before and after a purging procedure performed by a negative immunomagnetic BC cell separation. METHODS. Eighteen patients entered the study. Tumor contamination was assessed by conventional immunocytochemistry (ICC) and by a liquid culture assay developed in the study laboratory. Committed and more primitive hematopoietic progenitors were quantitated before and after the negative selection. Ten patients received HDC with purged PBSC support. RESULTS. Before purging, 4 of 18 PBSC collections were found to be contaminated by liquid culture; among these samples, only 1 was positive by ICC. Three of the four positive collections, including the ICC positive sample, became negative after immunomagnetic selection whereas BC cells still were present after the procedure in one harvest. A high recovery of both primitive and mature hematopoietic progenitors was found after the purging procedure. Patients receiving purged PBSC after myeloablation had a prompt and complete hematopoietic reconstitution, and no graft failure was observed at a median follow-up of 1 year. CONCLUSIONS. The preliminary results of the current study suggest that negative selection of BC cells is able to purge PBSC effectively while having no apparent affect on hematopoietic progenitor recovery in vitro and in vivo. (C) 2000 American Cancer Society.",
keywords = "Breast carcinoma, Immunomagnetic purging, Liquid culture immunocytochemistry, Peripheral blood stem cell (PBSC)",
author = "Paolo Pedrazzoli and Annalisa Lanza and Manuela Battaglia and {Da Prada}, {Gian Antonio} and Alberto Zambelli and Cesare Perotti and Luisa Ponchio and Laura Salvaneschi and {Della Cuna}, {Gioacchino Robustelli}",
year = "2000",
month = "6",
day = "15",
doi = "10.1002/1097-0142(20000615)88:12<2758::AID-CNCR14>3.0.CO;2-E",
language = "English",
volume = "88",
pages = "2758--2765",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Negative immunomagnetic purging of peripheral blood stem cell harvests from breast carcinoma patients reduces tumor cell contamination while not affecting hematopoietic recovery

AU - Pedrazzoli, Paolo

AU - Lanza, Annalisa

AU - Battaglia, Manuela

AU - Da Prada, Gian Antonio

AU - Zambelli, Alberto

AU - Perotti, Cesare

AU - Ponchio, Luisa

AU - Salvaneschi, Laura

AU - Della Cuna, Gioacchino Robustelli

PY - 2000/6/15

Y1 - 2000/6/15

N2 - BACKGROUND. Because tumor contamination of hematopoietic stem cell grafts may influence the outcome in breast carcinoma (BC) patients undergoing high dose chemotherapy (HDC), several ex vivo procedures for the purging of autologous harvests have been investigated. The authors studied the presence of epithelial tumor cells and the growth of hematopoietic progenitors in peripheral blood stem cell (PBSC) collections from patients with metastatic breast carcinoma before and after a purging procedure performed by a negative immunomagnetic BC cell separation. METHODS. Eighteen patients entered the study. Tumor contamination was assessed by conventional immunocytochemistry (ICC) and by a liquid culture assay developed in the study laboratory. Committed and more primitive hematopoietic progenitors were quantitated before and after the negative selection. Ten patients received HDC with purged PBSC support. RESULTS. Before purging, 4 of 18 PBSC collections were found to be contaminated by liquid culture; among these samples, only 1 was positive by ICC. Three of the four positive collections, including the ICC positive sample, became negative after immunomagnetic selection whereas BC cells still were present after the procedure in one harvest. A high recovery of both primitive and mature hematopoietic progenitors was found after the purging procedure. Patients receiving purged PBSC after myeloablation had a prompt and complete hematopoietic reconstitution, and no graft failure was observed at a median follow-up of 1 year. CONCLUSIONS. The preliminary results of the current study suggest that negative selection of BC cells is able to purge PBSC effectively while having no apparent affect on hematopoietic progenitor recovery in vitro and in vivo. (C) 2000 American Cancer Society.

AB - BACKGROUND. Because tumor contamination of hematopoietic stem cell grafts may influence the outcome in breast carcinoma (BC) patients undergoing high dose chemotherapy (HDC), several ex vivo procedures for the purging of autologous harvests have been investigated. The authors studied the presence of epithelial tumor cells and the growth of hematopoietic progenitors in peripheral blood stem cell (PBSC) collections from patients with metastatic breast carcinoma before and after a purging procedure performed by a negative immunomagnetic BC cell separation. METHODS. Eighteen patients entered the study. Tumor contamination was assessed by conventional immunocytochemistry (ICC) and by a liquid culture assay developed in the study laboratory. Committed and more primitive hematopoietic progenitors were quantitated before and after the negative selection. Ten patients received HDC with purged PBSC support. RESULTS. Before purging, 4 of 18 PBSC collections were found to be contaminated by liquid culture; among these samples, only 1 was positive by ICC. Three of the four positive collections, including the ICC positive sample, became negative after immunomagnetic selection whereas BC cells still were present after the procedure in one harvest. A high recovery of both primitive and mature hematopoietic progenitors was found after the purging procedure. Patients receiving purged PBSC after myeloablation had a prompt and complete hematopoietic reconstitution, and no graft failure was observed at a median follow-up of 1 year. CONCLUSIONS. The preliminary results of the current study suggest that negative selection of BC cells is able to purge PBSC effectively while having no apparent affect on hematopoietic progenitor recovery in vitro and in vivo. (C) 2000 American Cancer Society.

KW - Breast carcinoma

KW - Immunomagnetic purging

KW - Liquid culture immunocytochemistry

KW - Peripheral blood stem cell (PBSC)

UR - http://www.scopus.com/inward/record.url?scp=0034659937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034659937&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20000615)88:12<2758::AID-CNCR14>3.0.CO;2-E

DO - 10.1002/1097-0142(20000615)88:12<2758::AID-CNCR14>3.0.CO;2-E

M3 - Article

C2 - 10870058

AN - SCOPUS:0034659937

VL - 88

SP - 2758

EP - 2765

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -